[May 08, 2014] |
|
Research and Markets: Non-Small Cell Lung Cancer - Pipeline Review, H1 2014: 179 Companies Profiled
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/qsr7qv/nonsmall_cell)
has announced the addition of the "Non-Small
Cell Lung Cancer - Pipeline Review, H1 2014" report to their
offering.
This report provides comprehensive information on the therapeutic
development for Non-Small Cell Lung Cancer, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for
Non-Small Cell Lung Cancer and special features on late-stage and
discontinued projects.
Scope
-
The report provides a snapshot of the global therapeutic landscape of
Non-SmallCell Lung Cancer
-
The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
-
The report reviews key players involved in the therapeutics
development for Non-Small Cell Lung Cancer and enlists all their major
and minor projects
-
The report summarizes all the dormant and discontinued pipeline
projects
-
A review of the Non-Small Cell Lung Cancer products under development
by companies and universities/research institutes based on information
derived from company and industry-specific sources
-
Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
A detailed assessment of monotherapy and combination therapy pipeline
projects
-
Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of
target, MoA, route of administration and molecule type
-
Latest news and deals relating related to pipeline products
Reasons to buy
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Non-Small Cell Lung Cancer
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
For more information visit http://www.researchandmarkets.com/research/qsr7qv/nonsmall_cell
[ Back To TMCnet.com's Homepage ]
|